A combination of physical therapy and treatment with Medtronic's spinal-cord-stimulating devices helped three men with paraplegia move their extremities and briefly stand up on their own, The Wall Street Journal reports, regaining voluntary movement years after their injuries.
Edwards Lifesciences' Sapien XT beat out Medtronic's CoreValve in the first head-to-head comparison of the two firms' competing transcatheter aortic valve replacements (TAVR). This small trial won't be the last word, but it's seen as a weapon in Edwards' market arsenal versus its rival in a market estimated at $3 billion a year.
Medtronic pledged to plow ahead at some point with a new renal denervation trial, even as details of the company's failed U.S. pivotal study released March 29 revealed that the treatment for drug-resistant hypertension worked no better than a sham procedure.
Exact Sciences is celebrating positive results from a massive pivotal trial of its colorectal cancer diagnostic now published in The New England Journal of Medicine, an important achievement on the long regulatory road to approval.
St. Jude Medical is embarking on a massive postapproval study in Europe for its Nanostim leadless pacemaker, barely weeks after beginning U.S. trials for the same device.
The FDA will allow Biotronik to expand its ProMRI trial in the U.S. to implantable cardioverter-defibrillators (ICD), making the German device maker first to the starting line to test whether a patient with an ICD can safely undergo a magnetic resonance imaging (MRI) scan.
It's a crowded market for ophthalmological devices, and PowerVision wants to keep a leg up on the competition: As part of a new multicenter clinical study, the company implanted its innovative fluid-based intraocular lens into 10 patients.
Germany's Biotronik said 6-month results from a broader study of a drug-coated balloon to treat leg blood clots showed a major boost in the standard of care compared to standard balloon angioplasty.
Edwards Lifesciences reports initial success with the first three human implants of its Fortis mitral transcatheter heart valve, a necessary milestone if the California company is to succeed in both diversifying and broadening its market-leading presence in the transcatheter valve-replacement space.
Texas devicemaker Kinetic Concepts is touting the results of a new independent study that shows its wound-healing therapy system reduces operating room visits and hospital stays compared to the competition.